NGD-4715
Encyclopedia
NGD-4715 is a drug developed by Neurogen, which acts as a selective, non-peptide antagonist at the melanin concentrating hormone
receptor
MCH1
. In animal studies it has anxiolytic
, antidepressant
and anorectic
effects, and it has successfully passed Phase I clinical trial
s in humans.
Neurogen was acquired by Ligand Pharmaceuticals in August, 2009, and NGD-4715 was not listed among the key assets in the Business Wire article. All four laboratories were closed and sold, and no employees were retained. Neurogen's domain name is delisted. No reference to NGD-4715, nor MCH Antagonists exists on ligand.com as of 2011-09-04. Internet searches as of 2011-09-04 for Phase-II come up negative.
An email to Ligand Investor Relation received this response on 2011-09-07:
"NGD-4715, a MCH-1 antagonist, was under development at Neurogen for obesity. Neurogen terminated the program prior to Ligand’s acquisition. Ligand owns the wrights and currently has no plans for further development on the compound."
Melanin concentrating hormone
Melanin-concentrating hormone is a cyclic 19-amino acid orexinogenic hypothalamic peptide originally isolated from the pituitary gland of teleost fish where it controls skin pigmentation....
receptor
Receptor (biochemistry)
In biochemistry, a receptor is a molecule found on the surface of a cell, which receives specific chemical signals from neighbouring cells or the wider environment within an organism...
MCH1
Melanin-concentrating hormone receptor 1
Melanin-concentrating hormone receptor 1, also known as MCH1, is one of the human melanin-concentrating hormone receptors.-Function:...
. In animal studies it has anxiolytic
Anxiolytic
An anxiolytic is a drug used for the treatment of anxiety, and its related psychological and physical symptoms...
, antidepressant
Antidepressant
An antidepressant is a psychiatric medication used to alleviate mood disorders, such as major depression and dysthymia and anxiety disorders such as social anxiety disorder. According to Gelder, Mayou &*Geddes people with a depressive illness will experience a therapeutic effect to their mood;...
and anorectic
Anorectic
An anorectic or anorexic , also known as anorexigenic or appetite suppressant, is a dietary supplement and/or drug which reduces appetite, food consumption, and as a result, causes weight loss to occur.-List of anorectics:Numerous pharmaceutical compounds are marketed as appetite suppressants.The...
effects, and it has successfully passed Phase I clinical trial
Clinical trial
Clinical trials are a set of procedures in medical research and drug development that are conducted to allow safety and efficacy data to be collected for health interventions...
s in humans.
Neurogen was acquired by Ligand Pharmaceuticals in August, 2009, and NGD-4715 was not listed among the key assets in the Business Wire article. All four laboratories were closed and sold, and no employees were retained. Neurogen's domain name is delisted. No reference to NGD-4715, nor MCH Antagonists exists on ligand.com as of 2011-09-04. Internet searches as of 2011-09-04 for Phase-II come up negative.
An email to Ligand Investor Relation received this response on 2011-09-07:
"NGD-4715, a MCH-1 antagonist, was under development at Neurogen for obesity. Neurogen terminated the program prior to Ligand’s acquisition. Ligand owns the wrights and currently has no plans for further development on the compound."